VALUE-BASED PRECISION MEDICINE GENERATES MEASURABLE OUTCOMES FOR EVERY MEDICAL TREATMENT BASED ON MOLECULAR ANALYTICS
Precision medicine generates sustainable benefits for health insurance companies.
To assess the effectiveness of individual drug treatments it is necessary to measure the outcome for the patient. Is it meaningful and safe? Are medical treatments as far as possible without side effects as well as cost and / or value effective? Precision medicine reduces costs per case and year as well as expenditures and use considerations are rationally better evaluated. Health insurance funds need to find differentiated reimbursement schemes.
Healthcare insurances can be a main driver for better performance of our hospital and health systems by supporting the transformation towards precision medcine.
Health insurance executives have a central role as advocates for their insured patients and the society. Insurance systems need to integrate the precision medicine value-chain in order to participate from the value-based outcome of the PMA-Knowledge-Network. The new taxonomy of disease requires a precise and individual reimbursement for every patient and every hospital system.
The international „one-fits-all“-Diagnosed-Related-Groups reimbursement dogma will be replaced by a precision medicine reimbursement scheme. Healthcare insurances will benefit from lower costs, improved performance and outcome of the medical system thanks to the digitalisation and molecularisation of medicine.
The „Silicon-Valley“- Industry has improved the performance of almost every kind of industry sector and now medicine will benefit for the advantage of our patients and societies.
Healthcare Insurances will benefit by promoting and offering incentives for PRECISION PREVENTION FIRST:
